Log In
Print
BCIQ
Print
Print this Print this
 

Impavido, miltefosine

  Manage Alerts
Collapse Summary General Information
Company Knight Therapeutics Inc.
DescriptionAlkylphosphocholine analog that inhibits cholinephosphate cytidyltransferase
Molecular Target Cholinephosphate cytidyltransferase
Mechanism of ActionAntifungal agent
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationLeishmaniasis
Indication DetailsTreat cutaneous leishmaniasis; Treat Indian visceral leishmaniasis (VL); Treat leishmaniasis; Treat mucocutaneous leishmaniasis; Treat recurrent visceral leishmaniasis (VL) in HIV-infected patients who had failed 1-9 prior courses of standard therapy; Treat visceral and cutaneous leishmaniasis; Treat visceral leishmaniasis (VL)
Regulatory Designation

U.S. - Priority Review (Treat leishmaniasis);
U.S. - Priority Review (Treat cutaneous leishmaniasis);
U.S. - Priority Review (Treat visceral leishmaniasis (VL))

Partner

Roche; Zydus Cadila Group


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today